Lenvaxen is a brand of lenvatinib listed by Everest Pharmaceuticals Ltd. in 4 mg and 10 mg strengths.

Lenvatinib is a multi-target receptor tyrosine kinase inhibitor used in specified oncology indications.

Depending on jurisdiction, it is used for differentiated thyroid cancer, selected renal cell carcinoma, hepatocellular carcinoma and selected endometrial carcinoma.

It inhibits VEGFR, FGFR, RET, KIT and PDGFRα signaling pathways involved in angiogenesis and tumor-related cellular signaling.

They describe the amount of lenvatinib in each dosage unit. They do not by themselves indicate the correct daily dose.

Current U.S. labeled regimens are generally once daily, with the exact dose determined by indication and patient factors.

Current U.S. labeling allows it to be taken with or without food.

Under current U.S. labeling, if a missed dose cannot be taken within 12 hours, it should be skipped and the next dose taken at the regular time.

Yes. Hypertension is a clinically important adverse reaction and blood pressure monitoring is part of safe treatment.

Yes. Renal impairment and proteinuria are recognized risks and may require monitoring.

Yes. Hepatotoxicity is an important warning and liver function may require monitoring.

Hemorrhagic events can occur and may be serious. Significant bleeding requires prompt medical assessment.

Lenvatinib can cause fetal harm. Pregnancy planning and contraception requirements should be discussed with a healthcare professional.

Current U.S. labeling advises against breastfeeding during LENVIMA treatment.

Both are associated with lenvatinib, but they should not be described as identical products without product-specific evidence.

Everest Pharmaceuticals Ltd. lists Lenvaxen 4 and Lenvaxen 10 in its product portfolio.

Eisai reports that it discovered and developed lenvatinib and markets the reference product LENVIMA.

Yes. Depending on the indication, monitoring may include blood pressure, kidney and liver function, urine protein, thyroid function and electrolytes.

Compare the actual package, strength, manufacturer, batch or lot details, expiry date and other labeling with reliable product documentation.

No. Dose changes should be made only under qualified professional direction.